Viracta Therapeutics, Inc. (VIRX)
NASDAQ: VIRX · Real-Time Price · USD
0.152
-0.001 (-0.72%)
Nov 20, 2024, 4:00 PM EST - Market closed
Viracta Therapeutics Employees
Viracta Therapeutics had 40 employees as of December 31, 2023. The number of employees increased by 8 or 25.00% compared to the previous year.
Employees
40
Change (1Y)
8
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,082,225
Market Cap
5.99M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 40 | 8 | 25.00% |
| Dec 31, 2022 | 32 | 8 | 33.33% |
| Dec 31, 2021 | 24 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Cutera | 430 |
| Biora Therapeutics | 58 |
| Intelligent Bio Solutions | 50 |
| Ainos | 46 |
| ABVC BioPharma | 19 |
| Alzamend Neuro | 7 |
| NLS Pharmaceutics AG | 7 |
| CNS Pharmaceuticals | 5 |
VIRX News
- 8 days ago - Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan - GlobeNewsWire
- 6 months ago - Viracta Therapeutics Announces New Employment Inducement Grants - GlobeNewsWire
- 6 months ago - Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer - GlobeNewsWire
- 6 months ago - Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 7 months ago - Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference - GlobeNewsWire
- 7 months ago - Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma - GlobeNewsWire